Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy

被引：227

作者：

Goetz, Matthew P. ^{[1
]}

Sangkuhl, Katrin ^{[2
]}

Guchelaar, Henk-Jan ^{[3
]}

Schwab, Matthias ^{[4
,5
,6
]}

Province, Michael ^{[7
]}

Whirl-Carrillo, Michelle ^{[2
]}

Symmans, W. Fraser ^{[8
]}

McLeod, Howard L. ^{[9
]}

Ratain, Mark J. ^{[10
]}

Zembutsu, Hitoshi ^{[11
]}

Gaedigk, Andrea ^{[12
,13
]}

van Schaik, Ron H. ^{[14
,15
]}

Ingle, James N. ^{[1
]}

Caudle, Kelly E. ^{[16
]}

Klein, Teri E. ^{[2
]}

机构：

[1] Mayo Clin, Dept Oncol, Dept Mol Pharmacol & Expt Therapeut, Rochester, MN 55905 USA

[2] Stanford Univ, Dept Biomed Data Sci, Stanford, CA 94305 USA

[3] Leiden Univ, Dept Clin Pharm & Toxicol, Med Ctr, Leiden, Netherlands

[4] Dr Margarete Fischer Bosch Inst Clin Pharmacol, Stuttgart, Germany

[5] Univ Hosp, Dept Clin Pharmacol, Tubingen, Germany

[6] Univ Tubingen, Dept Biochem & Pharm, Tubingen, Germany

[7] Washington Univ, Sch Med, Div Stat Genom, St Louis, MO USA

[8] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA

[9] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[10] Univ Chicago, Ctr Personalized Therapeut, Chicago, IL 60637 USA

[11] Natl Canc Ctr, Div Human Genet, Res Inst, Tokyo, Japan

[12] Univ Missouri, Div Clin Pharmacol Toxicol & Therapeut Innovat, Childrens Mercy Kansas City, Kansas City, MO 64110 USA

[13] Univ Missouri, Dept Pediat, Kansas City, MO 64110 USA

[14] Erasmus MC, Int Expertctr Pharmacogenet, Dept Clin Chem, Rotterdam, Netherlands

[15] LKCH UMC Utrecht, Utrecht, Netherlands

[16] St Jude Childrens Res Hosp, Dept Pharmaceut Sci, 332 N Lauderdale St, Memphis, TN 38105 USA

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2018年 / 103卷 / 05期

基金：

美国国家卫生研究院;

关键词：

BREAST-CANCER PATIENTS; ADJUVANT TAMOXIFEN; ESTROGEN-RECEPTOR; IN-VITRO; POSTMENOPAUSAL WOMEN; ACTIVE METABOLITE; CODEINE THERAPY; GENOTYPE; CYP2C19-ASTERISK-2; POLYMORPHISMS;

D O I：

10.1002/cpt.1007

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Tamoxifen is biotransformed by CYP2D6 to 4-hydroxytamoxifen and 4-hydroxy N-desmethyl tamoxifen (endoxifen), both with greater antiestrogenic potency than the parent drug. Patients with certain CYP2D6 genetic polymorphisms and patients who receive strong CYP2D6 inhibitors exhibit lower endoxifen concentrations and a higher risk of disease recurrence in some studies of tamoxifen adjuvant therapy of early breast cancer. We summarize evidence from the literature and provide therapeutic recommendations for tamoxifen based on CYP2D6 genotype.

引用

页码：770 / 777

页数：8

共 57 条

[31] CLINICAL PHARMACOKINETICS OF ENDOCRINE AGENTS USED IN ADVANCED BREAST-CANCER
LONNING, PE
LIEN, EA
LUNDGREN, S
KVINNSLAND, S
[J]. CLINICAL PHARMACOKINETICS, 1992, 22 (05) : 327 - 358
[32] Tamoxifen Metabolite Concentrations, CYP2D6 Genotype, and Breast Cancer Outcomes
Madlensky, L.
Natarajan, L.
Tchu, S.
Pu, M.
Mortimer, J.
Flatt, S. W.
Nikoloff, D. M.
Hillman, G.
Fontecha, M. R.
Lawrence, H. J.
Parker, B. A.
Wu, A. H. B.
Pierce, J. P.
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 (05) : 718 - 725
[33] Maximov P.Y., 2014, NATL CANC I, V106
[34] Simulation with cells in vitro of tamoxifen treatment in premenopausal breast cancer patients with different CYP2D6 genotypes
Maximov, Philipp Y.
McDaniel, Russell E.
Fernandes, Daphne J.
Korostyshevskiy, Valeriy R.
Bhatta, Puspanjali
Muerdter, Thomas E.
Flockhart, David A.
Jordan, V. Craig
[J]. BRITISH JOURNAL OF PHARMACOLOGY, 2014, 171 (24) : 5624 - 5635
[35] Activity Levels of Tamoxifen Metabolites at the Estrogen Receptor and the Impact of Genetic Polymorphisms of Phase I and II Enzymes on Their Concentration Levels in Plasma
Muerdter, T. E.
Schroth, W.
Bacchus-Gerybadze, L.
Winter, S.
Heinkele, G.
Simon, W.
Fasching, P. A.
Fehm, T.
Eichelbaum, M.
Schwab, M.
Brauch, H.
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 (05) : 708 - 717
[36] Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer
Osborne, CK
Bardou, V
Hopp, TA
Chamness, GC
Hilsenbeck, SG
Fuqua, SAW
Wong, JM
Allred, DC
Clark, GM
Schiff, R
[J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (05) : 353 - 361
[37] Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer
Pagani, Olivia
Regan, Meredith M.
Walley, Barbara A.
Fleming, Gini F.
Colleoni, Marco
Lang, Istvan
Gomez, Henry L.
Tondini, Carlo
Burstein, Harold J.
Perez, Edith A.
Ciruelos, Eva
Stearns, Vered
Bonnefoi, Herve R.
Martino, Silvana
Geyer, Charles E., Jr.
Pinotti, Graziella
Puglisi, Fabio
Crivellari, Diana
Ruhstaller, Thomas
Winer, Eric P.
Rabaglio-Poretti, Manuela
Maibach, Rudolf
Ruepp, Barbara
Giobbie-Hurder, Anita
Price, Karen N.
Bernhard, Juerg
Luo, Weixiu
Ribi, Karin
Viale, Giuseppe
Coates, Alan S.
Gelber, Richard D.
Goldhirsch, Aron
Francis, Prudence A.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (02) : 107 - 118
[38] A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
Paik, S
Shak, S
Tang, G
Kim, C
Baker, J
Cronin, M
Baehner, FL
Walker, MG
Watson, D
Park, T
Hiller, W
Fisher, ER
Wickerham, DL
Bryant, J
Wolmark, N
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (27) : 2817 - 2826
[39] PharmGKB, GEN REF MAT CYP2D6
[40] Multigene and Drug Interaction Approach for Tamoxifen Metabolite Patterns Reveals Possible Involvement of CYP2C9, CYP2C19, and ABCB1
Powers, Jennifer L.
Buys, Saundra S.
Fletcher, Deborah
Melis, Roberta
Johnson-Davis, Kamisha L.
Lyon, Elaine
Malmberg, Elisabeth M.
McMillin, Gwendolyn A.
[J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 56 (12) : 1570 - 1581

← 1 2 3 4 5 6 →